Assembly Biosciences (ASMB) Price & Analysis

Compare

578 Followers

ASMB Stock Chart & Stats

$37.79

-$0.45(-2.59%)

At close: Jan 08 4:00 PM EST

$37.79

-$0.45(-2.59%)

Day’s Range― - ―

52-Week Range$7.75 - $39.71

Previous CloseN/A

Volume7.37K

Average Volume (3M)164.41K

Market Cap

$489.05M

Enterprise Value$66.63M

Total Cash (Recent Filing)$232.56M

Total Debt (Recent Filing)$2.75M

Price to Earnings (P/E)―

Beta1.38

Next Earnings

Mar 05, 2026

EPS Estimate

-0.86

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.72

Shares Outstanding15,560,009

10 Day Avg. Volume178,321

30 Day Avg. Volume164,409

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)2.84

Price to Sales (P/S)3.32

P/FCF Ratio-1.85

Enterprise Value/Market Cap0.14

Enterprise Value/Revenue1.79

Enterprise Value/Gross Profit9.82

Enterprise Value/Ebitda-1.60

Forecast

1Y Price Target

$41.75

Price Target Upside10.48% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentAssembly Biosciences reported 3Q25 results highlighted by continued progress across all three clinical franchises—HSV, HDV, and HBV—and by positive clinical data.

Market OpportunityA once-monthly oral treatment could redefine treatment paradigms and support a ~$1B U.S. market opportunity.

Strategic PartnershipsAssembly's strategic partnership with Gilead Sciences offers opt-in optionality, milestone funding, and a 40% U.S. profit-share structure.

Bears Say

Assembly Biosciences News

Assembly Biosciences price target raised to $40 from $29 at Mizuho

Mizuho analyst Salim Syed raised the firm’s price target on Assembly Biosciences (ASMB) to $40 from $29 and...

12d ago

ASMB

Assembly Biosciences reports Q3 EPS (72c), consensus (65c)

Reports Q3 revenue $10.79M, consensus $9.32M. “Our third quarter was marked by significant progress across our pipeline and...

22d ago

ASMB

Assembly Biosciences announces Phase 1b data for ABI-4334

Assembly Biosciences (ASMB) announced Phase 1b clinical data for its next-generation investigational capsid assembly modulator, CAM, ABI-4334 featured...

25d ago

ASMB

Assembly Biosciences: Strong Clinical Execution and Strategic Partnerships Drive Buy Rating

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Assembly Biosciences, with...

19d ago

ASMB

Assembly Biosciences Inc. Reports Q3 2025 Earnings

Assembly Biosciences Inc ( ($ASMB) ) has released its Q3 earnings. Here is a breakdown of the information...

21d ago

ASMB

ASMB Earnings this Week: How Will it Perform?

Assembly Biosciences Inc (ASMB) is scheduled to report 3rd quarter earnings on 11/06/2025. Regarding Q3 estimates, Wall Street...

28d ago

ASMB

Assembly Biosciences Advances HSV-2 Treatment Study with ABI-1179

Assembly Biosciences Inc (($ASMB)) announced an update on their ongoing clinical study. Study Overview: Assembly Biosciences Inc. is...

1M ago

ASMB

Assembly Biosciences’ Promising HSV-2 Treatment Study: Key Insights for Investors

Assembly Biosciences Inc (($ASMB)) announced an update on their ongoing clinical study. Study Overview: Assembly Biosciences Inc. is...

1M ago

ASMB

Assembly Biosciences’ ABI-6250 Study: A Potential Game-Changer in Hepatitis Treatment

Assembly Biosciences Inc (($ASMB)) announced an update on their ongoing clinical study. Assembly Biosciences Inc. is conducting a...

1M ago

ASMB

Assembly Biosciences files to sell 6.98M shares of commons stock for holders

16:22 EDT Assembly Biosciences (ASMB) files to sell 6.98M shares of commons stock for holders Published first on...

2M ago

ASMB

Promising Phase 1b Results for ABI-5366 Drive Buy Rating for Assembly Biosciences

Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Assembly Biosciences and keeping the price target...

2M ago

ASMB

Assembly Biosciences presents interim Phase 1b data for ABI-5366

Assembly Biosciences (ASMB) announced that interim Phase 1b clinical data for its long-acting herpes simplex virus helicase-primase inhibitor...

2M ago

ASMB

Amazon upgraded, Adobe downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

2M ago

Assembly Biosciences initiated with an Outperform at Citizens JMP

Citizens JMP analyst Roy Buchanan initiated coverage of Assembly Biosciences (ASMB) with an Outperform rating and $38 price...

2M ago

ASMB

ASMB FAQ

What was Assembly Biosciences’s price range in the past 12 months?

Assembly Biosciences lowest stock price was $7.75 and its highest was $39.70 in the past 12 months.

What is Assembly Biosciences’s market cap?

Assembly Biosciences’s market cap is $489.05M.

When is Assembly Biosciences’s upcoming earnings report date?

Assembly Biosciences’s upcoming earnings report date is Mar 05, 2026 which is in 93 days.

How were Assembly Biosciences’s earnings last quarter?

Assembly Biosciences released its earnings results on Nov 10, 2025. The company reported -$0.72 earnings per share for the quarter, beating the consensus estimate of -$0.821 by $0.101.

Is Assembly Biosciences overvalued?

According to Wall Street analysts Assembly Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Assembly Biosciences pay dividends?

Assembly Biosciences does not currently pay dividends.

What is Assembly Biosciences’s EPS estimate?

Assembly Biosciences’s EPS estimate is -0.86.

How many shares outstanding does Assembly Biosciences have?

Assembly Biosciences has 15,560,009 shares outstanding.

What happened to Assembly Biosciences’s price movement after its last earnings report?

Assembly Biosciences reported an EPS of -$0.72 in its last earnings report, beating expectations of -$0.821. Following the earnings report the stock price went up 3.305%.

Which hedge fund is a major shareholder of Assembly Biosciences?

Currently, no hedge funds are holding shares in ASMB

Assembly Biosciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-36.94%

Trailing 12-Months

Asset Growth

-29.95%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Assembly Biosciences

Assembly Biosciences, Inc. (ASMB) is a biotechnology company focused on developing innovative therapies for viral diseases, primarily targeting hepatitis B virus (HBV) infections. The company operates in the biopharmaceutical sector and is dedicated to advancing its proprietary drug candidates aimed at eradicating HBV and addressing other chronic viral infections. Assembly Biosciences leverages its expertise in virology and immunology to create therapies that can potentially cure these conditions.

Assembly Biosciences (ASMB) Earnings & Revenues

Historic Earnings Reports

ASMB Stock 12 Month Forecast

Average Price Target

$41.75

▲(10.48% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","51":"$51","20.25":"$20.3","30.5":"$30.5","40.75":"$40.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$41.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$38.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,20.25,30.5,40.75,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.05,32.50769230769231,33.965384615384615,35.42307692307692,36.88076923076923,38.33846153846154,39.79615384615384,41.253846153846155,42.71153846153846,44.169230769230765,45.62692307692308,47.08461538461539,48.54230769230769,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.05,31.873076923076923,32.69615384615385,33.519230769230774,34.34230769230769,35.16538461538462,35.988461538461536,36.81153846153846,37.63461538461539,38.457692307692305,39.28076923076923,40.103846153846156,40.926923076923075,{"y":41.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.05,31.584615384615386,32.11923076923077,32.65384615384615,33.18846153846154,33.723076923076924,34.25769230769231,34.792307692307695,35.32692307692308,35.86153846153846,36.396153846153844,36.93076923076923,37.465384615384615,{"y":38,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.15,"date":1717200000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":14.35,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":16.26,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.89,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.75,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.88,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":11.44,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.4,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.73,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.13,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.61,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.05,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >